Editorial on Targeted Systemic Therapies for Primary and Metastatic Brain Tumors1
Targeted systemic therapies for primary brain tumors
Chinese Clinical Oncology
2020;
9
(6)
:73
.
(27 December 2020)
Review Article on Targeted Systemic Therapies for Primary and Metastatic Brain Tumors1
Target treatment with stereotactic radiation for recurrent gliomas
Chinese Clinical Oncology
2020;
9
(6)
:74
.
(27 December 2020)
A narrative review of targeted therapy in meningioma, pituitary adenoma, and craniopharyngioma of the skull base
Chinese Clinical Oncology
2020;
9
(6)
:75
.
(27 December 2020)
A narrative review of targeted therapies in meningioma
Chinese Clinical Oncology
2020;
9
(6)
:76
.
(27 December 2020)
Characterization of molecular pathways for targeting therapy in glioblastoma
Chinese Clinical Oncology
2020;
9
(6)
:77
.
(27 December 2020)
Original Article
Real-world assessment of the effect of impact of tumor size on pathological complete response rates in triple negative breast cancer after neoadjuvant chemotherapy
Chinese Clinical Oncology
2020;
9
(6)
:78
.
(27 December 2020)
Review Article
A critical narrative review of radiotherapy for retroperitoneal soft tissue sarcoma
Chinese Clinical Oncology
2020;
9
(6)
:79
.
(27 December 2020)
Letter to the Editor
Collateral damage of COVID-19 pandemic on oncology clinical trials
Chinese Clinical Oncology
2020;
9
(6)
:80
.
(27 December 2020)
Editorial Commentary
Indolent non-Hodgkin lymphoma treatment in the new drugs era
Chinese Clinical Oncology
2020;
9
(6)
:81
.
(27 December 2020)
Real-world applications of deep convolutional neural networks in diagnostic cancer imaging
Chinese Clinical Oncology
2020;
9
(6)
:82
.
(27 December 2020)
Ramucirumab treatment in hepatocellular carcinoma
Chinese Clinical Oncology
2020;
9
(6)
:83
.
(27 December 2020)
Moving toward multi-dimensional biomarkers in cancer immunotherapy
Chinese Clinical Oncology
2020;
9
(6)
:84
.
(27 December 2020)
Disclosure:
1. The series “Targeted Systemic Therapies for Primary and Metastatic Brain Tumors” was commissioned by the Editorial office, Chinese Clinical Oncology without any sponsorship or funding. Jon Glass served as the unpaid Guest Editor for the series.